BR0212928A - Processo para tratamento de infecção viral de hapatite c em pacientes que não responderam a tratamento - Google Patents
Processo para tratamento de infecção viral de hapatite c em pacientes que não responderam a tratamentoInfo
- Publication number
- BR0212928A BR0212928A BR0212928-0A BR0212928A BR0212928A BR 0212928 A BR0212928 A BR 0212928A BR 0212928 A BR0212928 A BR 0212928A BR 0212928 A BR0212928 A BR 0212928A
- Authority
- BR
- Brazil
- Prior art keywords
- viral infection
- cifn
- treating
- treatment
- hapatitis
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000036142 Viral infection Diseases 0.000 title abstract 3
- 230000009385 viral infection Effects 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"PROCESSO PARA TRATAMENTO DE INFECçãO VIRAL DE HEPATITE C EM PACIENTES QUE NãO RESPONDERAM A TRATAMENTO". A presente invenção refere-se a processos para o tratamento de indivíduos tendo uma infecção viral por hepatite C (HCV), indivíduos esses que falharam em responder à terapia com IFN-<244> outro que interferon consensus (CIFN), ou que, após a cessação da terapia com IFN-<244> outro que CIFN, sofreram recorrência. Os processos envolvem, de um modo geral, um regime de tratamento compreendendo a administração de um primeiro regime de dosagem de CIFN, seguido por um segundo regime de dosagem de CIFN. Ribavirin é administrado em pelo menos o segundo regime de dosagem.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32610001P | 2001-09-28 | 2001-09-28 | |
| PCT/US2002/030006 WO2003028754A1 (en) | 2001-09-28 | 2002-09-20 | Method for treating hepatitis c virus infection in treatment failure patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0212928A true BR0212928A (pt) | 2004-10-13 |
Family
ID=23270817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0212928-0A BR0212928A (pt) | 2001-09-28 | 2002-09-20 | Processo para tratamento de infecção viral de hapatite c em pacientes que não responderam a tratamento |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20050031585A1 (pt) |
| EP (1) | EP1435997A4 (pt) |
| JP (1) | JP2005508926A (pt) |
| KR (1) | KR20040037191A (pt) |
| CN (1) | CN1561227A (pt) |
| AR (1) | AR036698A1 (pt) |
| BR (1) | BR0212928A (pt) |
| CA (1) | CA2461596A1 (pt) |
| HU (1) | HUP0401659A3 (pt) |
| IL (1) | IL160882A0 (pt) |
| MX (1) | MXPA04002915A (pt) |
| NO (1) | NO20041685L (pt) |
| WO (1) | WO2003028754A1 (pt) |
| ZA (1) | ZA200402231B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100316608A1 (en) * | 2009-06-15 | 2010-12-16 | Vijayaprakash Suppiah | Method of Determining A Response To Treatment With Immunomodulatory Composition |
| MX339762B (es) | 2011-09-28 | 2016-05-27 | Univ Autonoma Del Estado De Morelos | Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| AR088463A1 (es) | 2011-10-21 | 2014-06-11 | Abbvie Inc | Metodos para el tratamiento de hcv |
| CN104436197A (zh) | 2011-10-21 | 2015-03-25 | 艾伯维公司 | 至少两种直接作用抗病毒剂的组合产品 |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5980884A (en) * | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| US6127046A (en) * | 1997-12-04 | 2000-10-03 | Cummins Engine Company, Inc. | Formation of a graphite-free surface in a ferrous material to produce an improved intermetallic bond |
-
2002
- 2002-09-20 EP EP02761770A patent/EP1435997A4/en not_active Withdrawn
- 2002-09-20 US US10/490,456 patent/US20050031585A1/en not_active Abandoned
- 2002-09-20 CN CNA028191072A patent/CN1561227A/zh active Pending
- 2002-09-20 MX MXPA04002915A patent/MXPA04002915A/es unknown
- 2002-09-20 IL IL16088202A patent/IL160882A0/xx unknown
- 2002-09-20 HU HU0401659A patent/HUP0401659A3/hu unknown
- 2002-09-20 BR BR0212928-0A patent/BR0212928A/pt not_active IP Right Cessation
- 2002-09-20 CA CA002461596A patent/CA2461596A1/en not_active Abandoned
- 2002-09-20 WO PCT/US2002/030006 patent/WO2003028754A1/en not_active Ceased
- 2002-09-20 KR KR10-2004-7004603A patent/KR20040037191A/ko not_active Withdrawn
- 2002-09-20 JP JP2003532084A patent/JP2005508926A/ja active Pending
- 2002-09-27 AR ARP020103667A patent/AR036698A1/es unknown
-
2004
- 2004-03-19 ZA ZA200402231A patent/ZA200402231B/en unknown
- 2004-04-27 NO NO20041685A patent/NO20041685L/no not_active Application Discontinuation
-
2008
- 2008-02-20 US US12/034,542 patent/US20080213218A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0401659A2 (hu) | 2004-11-29 |
| EP1435997A4 (en) | 2006-03-01 |
| NO20041685L (no) | 2004-06-23 |
| JP2005508926A (ja) | 2005-04-07 |
| CA2461596A1 (en) | 2003-04-10 |
| KR20040037191A (ko) | 2004-05-04 |
| AR036698A1 (es) | 2004-09-29 |
| IL160882A0 (en) | 2004-08-31 |
| ZA200402231B (en) | 2005-03-22 |
| US20050031585A1 (en) | 2005-02-10 |
| US20080213218A1 (en) | 2008-09-04 |
| HUP0401659A3 (en) | 2005-02-28 |
| MXPA04002915A (es) | 2004-07-05 |
| EP1435997A1 (en) | 2004-07-14 |
| WO2003028754A1 (en) | 2003-04-10 |
| CN1561227A (zh) | 2005-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4001379B2 (ja) | ウィルス感染を治療する薬剤の調製におけるインターフェロンのサブタイプの使用 | |
| TWI317735B (en) | Methods and compositions for treating hepatitis c virus | |
| BR9913406A (pt) | Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção | |
| BR0312286A (pt) | pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae | |
| BR9911457A (pt) | Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv | |
| BR0316407A (pt) | Derivados de nucleosìdeo antiviral | |
| BR0213103A (pt) | Método para tratamento de infecção pelo vìrus da hepatite com um perfil de liberação de interferon multifásico | |
| AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
| CN1094642A (zh) | 治疗组合物 | |
| Burr et al. | Death after flumazepil | |
| BR0212917A (pt) | Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento | |
| BR9913333A (pt) | Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos | |
| BR0212928A (pt) | Processo para tratamento de infecção viral de hapatite c em pacientes que não responderam a tratamento | |
| KR970705563A (ko) | 항바이러스제로서의 4-(2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일)-2-시클로펜텐-1-메탄올 숙시네이트(4-(2-Amino-6-(Cyclopropylamino)-9H-Purin-9-yl)-2-Cyclopentene-1-Methanol Succinate as Antiviral Agent) | |
| BR9913951A (pt) | Tratamento de infecção de hepatite b com timosina alfa 1 em combinação com lamivudina e flamciclovir | |
| BR9915644A (pt) | Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus | |
| BR9916043A (pt) | Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes | |
| BR0311696A (pt) | Tratamento de hepatite c na população asiática com interferon-beta subcutâneo | |
| BR9808564A (pt) | Método de tratar um paciente tendo infecções por hiv | |
| Bauer | Antiviral chemotherapy: the first decade | |
| Braathen et al. | Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides | |
| Tan et al. | Dual benefit from intramuscular interferon-beta treatment in a patient with multiple sclerosis and chronic hepatitis-C virus infection | |
| DE60125377D1 (de) | Behandlung von hepatitis c mit thymosin, interferon und ribavirin | |
| Ferenci et al. | 476 Prospective evaluation of the 24 hour interferon (IFN) induced decline in hepatitis C virus genotype 1 load to predict sustained virologic response (SVR) to peginterferon-Alfa2A/ribavirin combination therapy with or without amantadine | |
| Sonawane et al. | A Systematic Review on Remdesivir for Preventing Covid 19 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A,7A E 8A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010. |